WO2000010552A3 - Use of anti-angiogenic agents for inhibiting vessel wall injury - Google Patents

Use of anti-angiogenic agents for inhibiting vessel wall injury Download PDF

Info

Publication number
WO2000010552A3
WO2000010552A3 PCT/US1999/019218 US9919218W WO0010552A3 WO 2000010552 A3 WO2000010552 A3 WO 2000010552A3 US 9919218 W US9919218 W US 9919218W WO 0010552 A3 WO0010552 A3 WO 0010552A3
Authority
WO
WIPO (PCT)
Prior art keywords
angiogenic agents
vessel wall
neointima
wall injury
treatment
Prior art date
Application number
PCT/US1999/019218
Other languages
French (fr)
Other versions
WO2000010552A2 (en
Inventor
Charles L Brown Iii
Steve Gorlin
Original Assignee
Global Vascular Concepts Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Global Vascular Concepts Inc filed Critical Global Vascular Concepts Inc
Priority to AU56871/99A priority Critical patent/AU5687199A/en
Publication of WO2000010552A2 publication Critical patent/WO2000010552A2/en
Publication of WO2000010552A3 publication Critical patent/WO2000010552A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients

Abstract

Use of anti-angiogenic agents to inhibit an undesireable response to vessel wall injury, including stent neointima, dialysis graft neointima, vascular graft induced neointima, and the treatment of benign hypertrophic scar formation as well as the treatment and passivation of unstable atherosclerotic plaques are provided. The invention provides for the use of catheter-based devices for enhancing the local delivery of anti-angiogenic agents into the endothelial tissues of blood vessels of the living body.
PCT/US1999/019218 1998-08-24 1999-08-24 Use of anti-angiogenic agents for inhibiting vessel wall injury WO2000010552A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU56871/99A AU5687199A (en) 1998-08-24 1999-08-24 Use of anti-angiogenic agents for inhibiting vessel wall injury

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9757998P 1998-08-24 1998-08-24
US60/097,579 1998-08-24

Publications (2)

Publication Number Publication Date
WO2000010552A2 WO2000010552A2 (en) 2000-03-02
WO2000010552A3 true WO2000010552A3 (en) 2000-11-23

Family

ID=22264134

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/019218 WO2000010552A2 (en) 1998-08-24 1999-08-24 Use of anti-angiogenic agents for inhibiting vessel wall injury

Country Status (2)

Country Link
AU (1) AU5687199A (en)
WO (1) WO2000010552A2 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5504074A (en) 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
US6908910B2 (en) 1993-08-06 2005-06-21 The Children's Medical Center Corporation Estrogenic compounds as anti-mitotic agents
US7772220B2 (en) * 2004-10-15 2010-08-10 Seo Hong Yoo Methods and compositions for reducing toxicity of a pharmaceutical compound
WO2000024415A2 (en) * 1998-10-28 2000-05-04 Cornell Research Foundation, Inc. Methods for regulating angiogenesis and vascular integrity using trk receptor ligands
US7087592B1 (en) 1999-08-23 2006-08-08 Entre Med, Inc. Compositions comprising purified 2-methoxyestradiol and methods of producing same
ES2215069T3 (en) * 1999-09-21 2004-10-01 Institut De Cardiologie De Montreal LOCAL SUPPLY OF 17-BETA ESTRADIOL TO AVOID INTIMATE VASCULAR HYPERPLASIA AND TO IMPROVE VASCULAR ENDOTELIAL FUNCTION AFTER VASCULAR DAMAGE.
ES2288487T3 (en) * 1999-11-09 2008-01-16 Pharmacia Corporation USE OF EPLERENONE FOR TREATMENT OF RESTENOSIS.
DE19957342A1 (en) * 1999-11-29 2001-05-31 Gruenenthal Gmbh Treatment of interleukin (IL)-12 mediated illnesses comprises simultaneous administration of thalidomide or analogue and antiinflammatory cytokine
US7182953B2 (en) * 1999-12-15 2007-02-27 Celgene Corporation Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
US6716829B2 (en) 2000-07-27 2004-04-06 Pharmacia Corporation Aldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders
CA2416152A1 (en) * 2000-07-27 2002-02-07 Pharmacia Corporation Aldosterone blocker therapy to prevent or treat inflammation-related disorders
US6995278B2 (en) 2000-08-18 2006-02-07 Entre Med, Inc. Antiangiogenic agents
US7135581B2 (en) 2000-08-18 2006-11-14 Entremed, Inc. Antiangiogenic agents
US6436629B1 (en) * 2000-10-27 2002-08-20 The Regents Of The University Of California Modulating angiogenesis
AU2001288386B2 (en) * 2000-11-27 2006-11-02 Entremed, Inc. 2-substituted estrogens as antiangiogenic agents
HUP0302732A2 (en) * 2001-01-12 2003-12-29 Société de Conseil de Recherches et d'Applications Scientifiques, S.A.S. Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof
DE10115740A1 (en) 2001-03-26 2002-10-02 Ulrich Speck Preparation for restenosis prophylaxis
US6625486B2 (en) 2001-04-11 2003-09-23 Advanced Cardiovascular Systems, Inc. Method and apparatus for intracellular delivery of an agent
AU4239302A (en) * 2001-06-28 2003-01-02 Pfizer Products Inc. Benzoic acid substituted benzopyrans for the treatment of atherosclerosis
MXPA04007128A (en) * 2002-01-30 2005-03-31 Pharmacia Corp Aldosterone antagonist and non-steroidal anti-inflammatory agent combination therapy to prevent or treat cardiovascular disorders.
CA2482147A1 (en) * 2002-04-22 2003-10-30 Research Foundation Itsuu Laboratory Medicament for therapeutic treatment of vascular disease
WO2004024206A1 (en) * 2002-09-12 2004-03-25 Estrogen Vascular Technology, Llc Apparatus and method for delivering compounds to a living organism
DE10244847A1 (en) 2002-09-20 2004-04-01 Ulrich Prof. Dr. Speck Medical device for drug delivery
WO2005007211A2 (en) * 2003-07-03 2005-01-27 Medtronic Vascular Inc. Medical devices with proteasome inhibitors for the treatment of restenosis
WO2005061448A1 (en) * 2003-12-24 2005-07-07 Monash University Compositions and methods for treating vascular conditions
JP2007529426A (en) 2004-03-12 2007-10-25 エントレメッド インコーポレイテッド Anti-angiogenic drugs
WO2006034345A2 (en) 2004-09-20 2006-03-30 Research Development Foundation Avicin-coated stents
JP2008521935A (en) * 2004-12-02 2008-06-26 アボット・ラボラトリーズ Use of a compound that activates vitamin D receptor to reduce intimal hyperplasia, smooth muscle cell proliferation and restenosis in mammals
US7286295B1 (en) 2005-11-30 2007-10-23 Sandia Corporation Microoptical compound lens
WO2007109312A2 (en) 2006-03-20 2007-09-27 Entremed, Inc. Disease modifying anti-arthritic activity of 2-methoxyestradiol
US8500687B2 (en) 2008-09-25 2013-08-06 Abbott Cardiovascular Systems Inc. Stent delivery system having a fibrous matrix covering with improved stent retention
EP2356998A1 (en) * 2010-02-17 2011-08-17 Université de Liège A pharmaceutical composition for treatment of thrombosis-related diseases comprising a fragment of prolactin (PRL)-growth hormone (GH) - placental lactogen (PL)-family protein
CN113332298A (en) * 2021-05-27 2021-09-03 成都医学院 New use of minocycline as a tyrosine kinase inhibitor

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991019731A1 (en) * 1990-06-11 1991-12-26 The Upjohn Company Steroids which inhibit angiogenesis
US5096892A (en) * 1988-05-27 1992-03-17 The Children's Medical Center Corporation Arylsulfatase inhibition and potentiation of angiostatic steroids and heparin
WO1992015286A1 (en) * 1991-02-27 1992-09-17 Nova Pharmaceutical Corporation Anti-infective and anti-inflammatory releasing systems for medical devices
US5286254A (en) * 1990-06-15 1994-02-15 Cortrak Medical, Inc. Drug delivery apparatus and method
WO1994026888A1 (en) * 1993-05-19 1994-11-24 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of proliferation of vascular smooth muscle cell
WO1995003036A1 (en) * 1993-07-19 1995-02-02 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
WO1995005866A1 (en) * 1993-08-27 1995-03-02 Cortrak Medical Inc. Simultaneous angioplasty and drug delivery
WO1997016197A1 (en) * 1995-10-30 1997-05-09 Les Laboratoires Aeterna Inc. Extracts of shark cartilage
WO1998030255A2 (en) * 1997-01-09 1998-07-16 Localmed, Inc. Localized intravascular delivery of antioxidant substances for inhibition of restenosis in recanalized blood vessels
US5788979A (en) * 1994-07-22 1998-08-04 Inflow Dynamics Inc. Biodegradable coating with inhibitory properties for application to biocompatible materials
WO1999009982A1 (en) * 1997-08-25 1999-03-04 Harold Brem Prevention of adhesions and excessive scar formation using angiogenesis inhibitors

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5096892A (en) * 1988-05-27 1992-03-17 The Children's Medical Center Corporation Arylsulfatase inhibition and potentiation of angiostatic steroids and heparin
WO1991019731A1 (en) * 1990-06-11 1991-12-26 The Upjohn Company Steroids which inhibit angiogenesis
US5286254A (en) * 1990-06-15 1994-02-15 Cortrak Medical, Inc. Drug delivery apparatus and method
WO1992015286A1 (en) * 1991-02-27 1992-09-17 Nova Pharmaceutical Corporation Anti-infective and anti-inflammatory releasing systems for medical devices
WO1994026888A1 (en) * 1993-05-19 1994-11-24 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of proliferation of vascular smooth muscle cell
WO1995003036A1 (en) * 1993-07-19 1995-02-02 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
WO1995005866A1 (en) * 1993-08-27 1995-03-02 Cortrak Medical Inc. Simultaneous angioplasty and drug delivery
US5788979A (en) * 1994-07-22 1998-08-04 Inflow Dynamics Inc. Biodegradable coating with inhibitory properties for application to biocompatible materials
WO1997016197A1 (en) * 1995-10-30 1997-05-09 Les Laboratoires Aeterna Inc. Extracts of shark cartilage
WO1998030255A2 (en) * 1997-01-09 1998-07-16 Localmed, Inc. Localized intravascular delivery of antioxidant substances for inhibition of restenosis in recanalized blood vessels
WO1999009982A1 (en) * 1997-08-25 1999-03-04 Harold Brem Prevention of adhesions and excessive scar formation using angiogenesis inhibitors

Also Published As

Publication number Publication date
WO2000010552A2 (en) 2000-03-02
AU5687199A (en) 2000-03-14

Similar Documents

Publication Publication Date Title
WO2000010552A3 (en) Use of anti-angiogenic agents for inhibiting vessel wall injury
HK1047404B (en) Vascular coating composition
WO2000013702A3 (en) Use of an angiogenic factor for the treatment of microvascular angiopathies
AU2002251898A1 (en) Guidewire and lock mechanism
BR9710682A (en) Compositions and methods for treating or preventing diseases of the body's pathways
HK1024153A1 (en) Surgical retractor
MXPA03006557A (en) Method and apparatus to remove substances from vessels of the heart and other parts of the body to minimize or avoid renal or other harm or dysfunction.
PT997474E (en) ANTITROMBOTIC AGENTS
WO2006017470A3 (en) Device and method for treating a vessel
WO2002000210A3 (en) Use of agents capable of reducing uric acid levels for the treatment of cardiovascular disease
WO2001049295A9 (en) Use of low dosage bisphosphonates to inhibit cardiac and arterial calcification
AU4124089A (en) Use of ACE-inhibitor for suppressing the formation of neointima and the reduction of the vascular lumen by vascular wall thickening after vascular damage
WO2002011747A3 (en) Transglutaminase for inhibiting angiogenesis
WO2001035997A3 (en) Use of low-dose pdt to inhibit restenosis
EP1743656A3 (en) Pharmaceutical combination for the treatment of benign prostatic hyperplasia or for the long-term prevention of acute urinary retention
EP1417971A3 (en) Use of an angiogenic factor for the treatment of microvascular angiopathies
EP1222854A4 (en) Prevention and treatment of diseases associated with blood coagulation
WO2000071716A3 (en) Vascular endothelial growth factor dimers
CA2164022A1 (en) Enhanced lubricity guidewire
TR200501763T2 (en) Treatment and screening methods
WO1998030255A3 (en) Localized intravascular delivery of antioxidant substances for inhibition of restenosis in recanalized blood vessels
WO2004045531A3 (en) Protection of cardiac myocardium
NO995459L (en) Tissue factor for influencing blood vessel formation
WO2006036804A3 (en) Methods for the treatment and prevention of diseases of biological conduits
WO2007112025A3 (en) Composite vascular prosthesis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase